Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
The Breast Journal|December 24, 2025
Adherence to Aromatase Inhibitor Therapy in Breast Cancer: Insights From a Multicenter Italian StudyMaria Agnese Fabbri, Alberto Fulvi, Matteo Vergati, et al.
Frontiers in Oncology|July 13, 2023
Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative studyAgnese Fabbri, Fabrizio Nelli, Andrea Botticelli, et al.
The Oncologist|November 23, 2023
Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL StudyAndrea Botticelli, Roberta Caputo, Simone Scagnoli, et al.
Tumori|September 20, 2023
PD-L1 testing in metastatic triple negative breast cancer: Results of an Italian surveyBruna Cerbelli, Alessio Cirillo, Giulia Pomati, et al.
NPJ Breast Cancer|July 17, 2024
Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY studySimone Scagnoli, Simona Pisegna, Angela Toss, et al.
Breast (Edinburgh, Scotland)|April 28, 2026
Real-world effectiveness of CDK4/6 inhibitors in older patients with HR+/HER2- advanced breast cancer: a sub-analysis of the multicenter, PALMARES-2 studyFrancesca Ligorio, Leonardo Provenzano, Giuseppe Fotia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 20, 2025
The Impact of Concordance Between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the Rome TrialAndrea Botticelli, Chiara Cremolini, Simone Scagnoli, et al.
Breast (Edinburgh, Scotland)|January 31, 2026
Effectiveness comparison of first-line CDK4/6 inhibitors in patients with hormone-positive HER2-negative advanced breast cancer according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2Giacomo Mazzoli, Leonardo Provenzano, Maria Vittoria Dieci, et al.
Nature Medicine|September 30, 2025
Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trialPaolo Marchetti, Giuseppe Curigliano, Mauro Biffoni, et al.
Breast (Edinburgh, Scotland)|May 27, 2025
Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitorsRoberta Scafetta, Marco Donato, Carla Gullotta, et al.
Pageof 4